Back to News
Market Impact: 0.25
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
Source: marketbeat.com
Healthcare & BiotechCompany FundamentalsAnalyst Insights
Dogwood Therapeutics (DWTX) said its Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain has enrolled over 230 patients, with top-line data expected later this fall. The update is a positive clinical milestone ahead of upcoming efficacy/safety readouts, though no trial results were disclosed yet.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
DWTX0.25
More News
- The IPO drought is driving private equity-owned companies to the debt market to pay investors
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- FDA approves Enspryng for thyroid eye disease treatment
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’
- Hybe shares jump 10% as K-pop sensation BTS' tour lifts earnings hopes
- Brian Sullivan: Why the 'real' price of oil is likely $30-$40 higher than where it is now
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements
- Choosing an AI Copilot for Equity Research